Insulin-like growth factor-binding protein-3 in breast cancer: analysis with tissue microarray

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1131-1136

  Sheen Chen, Shyr Ming ^a,c   Zhang, Hao ^b   Huang, Chao Cheng ^a   Tang, Rei Ping ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b XIAMEN CHANG GUNG HOSPITAL   (China)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Breast cancer; IGFBP 3; Tissue microarray

Indexed keywords

ESTROGEN RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3;

AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 64949122409     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Holdaway IM, Mason BH, Lethaby VS and Colao A: Serum insulin-like growth factor-1 and insulin-likegrowth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 73: 905-908, 2003.
2. Khandwawala HM, McCurcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244, 2000.
3. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins:biological actions.Endocr Rev 16: 3-34, 1995.
4. Salahifar H, Firth SM, Baxter RC and Martin JL: Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cell. Growth Hormones IGF Res 10: 267-377, 2000.
5. NickersonT, Huynh H and Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells Biochem Biophys Res Commun 237: 690-693, 1997.
6. Fontana JA, Burrows-Mezu A, Clemmons DR and Leroith D: Retinoid modulation of insulin-like growth factor-binding protein and inhibition of breast carcinoma proliferation. Endocrinology 128: 1115-1122,1991.
7. Martin JL, Coverley JA, Pattison ST and Baxter RC: Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136: 1219-1226, 1995.
8. ChenJC, Shao ZM, Sheikh MS and Yang CM: Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I(IGF-I)- mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158: 69-78, 1994.
9. Martin JL and Pattison SL: Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 141: 2401-2409, 2000.
10. Agus-Collins T, Adams-Cambell LL, Kim KS and Cullen KJ: Insulin-like growth factor-I and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 24: 199-206, 2000.
11. Figueroa JA, Jackson JG, McGuire WL and Martin JL: Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52: 196-205, 1993.
12. Moch H, Kononen J, Kallioniemi OP and Sauter G: Tissue Microarrays: what will they bring to molecular and anatomic pathology. Advances in Anatomic Pathology 8: 14-20, 2001.
13. Rijn MVD and Gilks CB: Applications of microarrays to histopathology. Histopathology 44: 97-108, 2004.
14. The World Health Organization Histological Typing of Breast Tumor, 2nd ed. Am J Clin Pathol 78: 808-816, 1982.
15. Sheen-Chen SM, Chen WJ, Eng HL and Chou FF: Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Research and Treatment 43: 211-215, 1997.
16. Sheen-Chen SM, Eng HL, Chou FF and Chen WJ: The prognostic significance of proliferating cell nuclear antigen in patients with lymph node-positive breast cancer. Arch Surg 132: 264-267, 1997.
17. Sheen-Chen SM, Chen WJ, Eng HL and Chou FF: Serum- soluble interleukin-2 receptor concentrations in patients with breast cancer: A preliminary report. Chang Gung Med J 21: 133- 138,1998.
18. Sheen-Chen SM, Chou FF, Eng HL and Chen WJ: An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 116: 510-515, 1994.
19. Sheen-Chen SM, Eng HL, Sheen CW, Cheng YF and Chou FF: Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. Anticancer Res 17: 282-236, 1997.
20. Sheen-Chen SM, Chen WJ, Eng HL and Chou FF: Evaluation of the prognostic value of serum soluble CD44 in patients with breast cancer, Cancer Investigation 17: 581-585, 1999.
21. Perrone EE, Theoharis C, Mucci NR, Hayasaka S and Santer G: Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J Natl Cancer Inst 92(11): 937-939,2000.
22. Yee D: The insulin-like growth factors and breast cancer revised. Br Cancer Res Treat 47: 197-199, 1998.
23. Hankinson SE, Willett WC, Colditz GA, Hunter DJ and Rocha RL: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998.
24. Rasmussen AA and Cullen KJ: Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47: 219-233, 1998.
25. Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Br Cancer Res Treat 47: 283-293, 1998.
26. Rocha RL, Hilsenbeck SG, Jackson JG, Lee Av, Figueroa JA and Yee D: Correlation of insulin-like growth factor-binding protein- 3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors withpoor prognostic features. J Natl Cancer Inst 88: 601-606, 1996.
27. Yu H, Levesque MA, Khostavi MJ, Papanastasiou-Diamandi A, Clark GM and Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 74: 1242-1247, 1996.
28. Kononen J, Bubendorf L, Kallioniemi A and Patti TC: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
29. Moch H, Kononen J, Kallioniemi OP and Sauter G: Tissue Microarrays: what will they bring to molecular and anatomic pathology. Advances in Anatomic Pathology 8: 14-20, 2001.
30. Rijn MVD and Gilks CB: Applications of microarrays to histopathology. Histopathology 44: 97-108, 2004.
31. Schraml P, Kononen J, Bubendorf L and Gilks CB: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966-1975, 1999.
32. Torhorst J, Bucher C, Kononen J and Santer G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256, 2001.
33. Zhang D, Salto-Tellez M, Putti TC, Do E and Koay ES: Reliability of tissue microarray in detecting protein expression and gene amplification in breast cancer. Modern Pathol 16: 79- 84, 2003.
34. Radhakrishnan R, Solomon A and Satyamoorthy K: Tissue microarray - A high-through molecular analysis in head and neck cancer. J Oral Pathol Med 37: 166-176, 2008.
35. Crabb SJ, Bajdik CD and Leung S: Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph node be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res 10(1): R6, 2008.